Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Coagulation Factor VIII and Coagulation Factor IX), Sector (Public Sector and Private Sector): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global plasma fractionation market accounted for $18,222 million in 2019, and is expected to reach $23,006 million by 2027, registering a CAGR of 6.2% from 2020 to 2027.
Fractionation is a mechanical process carried out to separate a certain quantity of mixture. Plasma is the liquid part of blood which is yellowish and holds blood cells. Plasma fractionation is carried out to separate high quality, proteinaceous products such as albumin and immunoglobulins. These derived products are known as plasma derivatives obtained from fractionation. Moreover, these products are used in various medical fields such as in neurology, hematology, critical care, and immunology. For instance, in critical care, plasma is prescribed to prevent and stop bleeding. In addition, plasma products are widely used in clinical research laboratories and hospitals. In addition, there are majorly two types of players that conduct plasma fractionation such as public players and private players. Moreover, public players include the companies which are non-profit government run bodies that fractionate plasma. Similarly, private players include the companies which earn profit by the sale of fractionated plasma products.
Surge in geriatric population across the globe, which is predisposed to various rare diseases that require use of plasma derivatives is the major factor that boosts the market growth. Moreover, rise in use of immunoglobulins and alpha-1-antitrypsin in areas of medicine worldwide also fuels growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes toward growth of this market.
In addition, favorable government support to spread awareness related to use of plasma derived products also fuels growth of the plasma fractionation market. However, fractionation is an expensive procedure, which includes collection of pooled blood from a large group of individuals. These individuals undergo screening to detect and avoid diseases, which can be transmitted through plasma. Furthermore, plasma-derived products are further screened post formulation to destroy any bacteria and viruses present in the product. These steps, in turn, make plasma derived products expensive which serves as a hindrance to the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period. Furthermore, there are advancements in processes, improved formulations, and increase in production efficiency. Advancement in technology leads to improved process of plasma manufacturing, hence leading to growth of the market
The global plasma fractionation market is segmented on the basis of product, sector, and country. On the basis of product, the market is divided into albumin, immunoglobulins, coagulation factor VIII, and coagulation factor IX. By sector, the market is classified into public sector and private sector. By country, it is analyzed across Turkey, Russia, Korea, Kingdom of Saudi Arabia, Taiwan, Indonesia, Thailand, Malaysia, Canada, Vietnam and rest of the world.
The global plasma fractionation market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum plasma fractionation market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Grifols SA, Baxter International Inc, CSL LTD., Bio Product Laboratory, Octapharma AG, Sanquin, Laboratoire Franais Du Fractionnement Et Des Biotechnologies, Kedrion, Biotest, and Takeda Pharmaceuticals.
KEY BENEFITS FOR STAKEHOLDERS
Fractionation is a mechanical process carried out to separate a certain quantity of mixture. Plasma is the liquid part of blood which is yellowish and holds blood cells. Plasma fractionation is carried out to separate high quality, proteinaceous products such as albumin and immunoglobulins. These derived products are known as plasma derivatives obtained from fractionation. Moreover, these products are used in various medical fields such as in neurology, hematology, critical care, and immunology. For instance, in critical care, plasma is prescribed to prevent and stop bleeding. In addition, plasma products are widely used in clinical research laboratories and hospitals. In addition, there are majorly two types of players that conduct plasma fractionation such as public players and private players. Moreover, public players include the companies which are non-profit government run bodies that fractionate plasma. Similarly, private players include the companies which earn profit by the sale of fractionated plasma products.
Surge in geriatric population across the globe, which is predisposed to various rare diseases that require use of plasma derivatives is the major factor that boosts the market growth. Moreover, rise in use of immunoglobulins and alpha-1-antitrypsin in areas of medicine worldwide also fuels growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes toward growth of this market.
In addition, favorable government support to spread awareness related to use of plasma derived products also fuels growth of the plasma fractionation market. However, fractionation is an expensive procedure, which includes collection of pooled blood from a large group of individuals. These individuals undergo screening to detect and avoid diseases, which can be transmitted through plasma. Furthermore, plasma-derived products are further screened post formulation to destroy any bacteria and viruses present in the product. These steps, in turn, make plasma derived products expensive which serves as a hindrance to the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period. Furthermore, there are advancements in processes, improved formulations, and increase in production efficiency. Advancement in technology leads to improved process of plasma manufacturing, hence leading to growth of the market
The global plasma fractionation market is segmented on the basis of product, sector, and country. On the basis of product, the market is divided into albumin, immunoglobulins, coagulation factor VIII, and coagulation factor IX. By sector, the market is classified into public sector and private sector. By country, it is analyzed across Turkey, Russia, Korea, Kingdom of Saudi Arabia, Taiwan, Indonesia, Thailand, Malaysia, Canada, Vietnam and rest of the world.
The global plasma fractionation market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum plasma fractionation market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Grifols SA, Baxter International Inc, CSL LTD., Bio Product Laboratory, Octapharma AG, Sanquin, Laboratoire Franais Du Fractionnement Et Des Biotechnologies, Kedrion, Biotest, and Takeda Pharmaceuticals.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global plasma fractionation market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
- By Product
- Albumin
- Immunoglobulin
- Coagulation Factor VIII
- Coagulation Factor IX
- By Sector
- Public Sector
- Private Sector
- By Country
- Turkey
- Russia
- South Korea
- Saudi Arabia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Canada
- Vietnam
- Rest of the World
- List of key players profiled in the report:
- Grifols SA
- Baxter International Inc
- CSL LTD.
- Bio Product Laboratory
- Octapharma AG
- Sanquin
- Laboratoire Franais Du Fractionnement Et Des Biotechnologies
- Kedrion
- Biotest
- Takeda Pharmaceuticals
- China Biologic Products
- China Biologic Products.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.3.1.Bargaining power of buyers
3.3.2.Bargaining power of suppliers
3.3.3.Thereat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in geriatric population across, coupled with rise in prevalence of rare diseases
3.5.1.2.Rise in use of immunoglobulins in medicine
3.5.1.3.Increase in number of plasma collection centers across the globe
3.5.2.Restraint
3.5.2.1.High cost of plasma derived products
3.5.3.Opportunity
3.5.3.1.High growth potential in emerging economies
3.5.4.Impact Analysis
CHAPTER 4:PLASMA FRACTIONATION MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Albumin
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast, by country
4.3.Immunoglobulins
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast, by country
4.4.Coagulation factor VIII
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast, by country
4.5.Coagulation factor IX
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast, by country
CHAPTER 5:PLASMA FRACTIONATION MARKET, BY SECTOR
5.1.Overview
5.1.1.Market size and forecast
5.2.Public Sector
5.2.1.Market size and forecast, by region
5.3.Private Sector
5.3.1.Market size and forecast, by country
CHAPTER 6:PLASMA FRACTIONATION MARKET, BY COUNTRY
6.1.Overview
6.1.1.Market size and forecast
6.2.Turkey
6.2.1.Key market trends and growth opportunities
6.2.2.Market size and forecast, by product
6.2.3.Market size and forecast, by sector
6.3.Russia
6.3.1.Key market trends and growth opportunities
6.3.2.Market size and forecast, by product
6.3.3.Market size and forecast, by sector
6.4.Korea (South Korea)
6.4.1.Key market trends and growth opportunities
6.4.2.Market size and forecast, by product
6.4.3.Market size and forecast, by sector
6.5.Kingdom of Saudi Arabia
6.5.1.Key market trends and growth opportunities
6.5.2.Market size and forecast, by product
6.5.3.Market size and forecast, by sector
6.6.Taiwan
6.6.1.Key market trends and growth opportunities
6.6.2.Market size and forecast, by product
6.6.3.Market size and forecast, by sector
6.7.Indonesia
6.7.1.Key market trends and growth opportunities
6.7.2.Market size and forecast, by product
6.7.3.Market size and forecast, by sector
6.8.Thailand
6.8.1.Key market trends and growth opportunities
6.8.2.Market size and forecast, by product
6.8.3.Market size and forecast, by sector
6.9.Malaysia
6.9.1.Key market trends and growth opportunities
6.9.2.Market size and forecast, by product
6.9.3.Market size and forecast, by sector
6.10.Canada
6.10.1.Key market trends and growth opportunities
6.10.2.Market size and forecast, by product
6.10.3.Market size and forecast, by sector
6.11.Vietnam
6.11.1.Key market trends and growth opportunities
6.11.2.Market size and forecast, by product
6.11.3.Market size and forecast, by sector
6.12.Rest of the World
6.12.1.Key market trends and growth opportunities
6.12.2.Market size and forecast, by product
6.12.3.Market size and forecast, by sector
CHAPTER 7:COMPANY PROFILES
7.1.BAXTER INTERNATIONAL INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.BIO PRODUCTS LABORATORY
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Key strategic moves and developments
7.3.BIOTEST AG
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.CSL LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRIFOLS SA
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.KEDRION S.P.A. (KEDRION BIOPHARMA INC.)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.LFB S. A
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.8.OCTAPHARMA AG
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.SANQUIN BLOOD SUPPLY FOUNDATION
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.3.1.Bargaining power of buyers
3.3.2.Bargaining power of suppliers
3.3.3.Thereat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in geriatric population across, coupled with rise in prevalence of rare diseases
3.5.1.2.Rise in use of immunoglobulins in medicine
3.5.1.3.Increase in number of plasma collection centers across the globe
3.5.2.Restraint
3.5.2.1.High cost of plasma derived products
3.5.3.Opportunity
3.5.3.1.High growth potential in emerging economies
3.5.4.Impact Analysis
CHAPTER 4:PLASMA FRACTIONATION MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Albumin
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast, by country
4.3.Immunoglobulins
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast, by country
4.4.Coagulation factor VIII
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast, by country
4.5.Coagulation factor IX
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast, by country
CHAPTER 5:PLASMA FRACTIONATION MARKET, BY SECTOR
5.1.Overview
5.1.1.Market size and forecast
5.2.Public Sector
5.2.1.Market size and forecast, by region
5.3.Private Sector
5.3.1.Market size and forecast, by country
CHAPTER 6:PLASMA FRACTIONATION MARKET, BY COUNTRY
6.1.Overview
6.1.1.Market size and forecast
6.2.Turkey
6.2.1.Key market trends and growth opportunities
6.2.2.Market size and forecast, by product
6.2.3.Market size and forecast, by sector
6.3.Russia
6.3.1.Key market trends and growth opportunities
6.3.2.Market size and forecast, by product
6.3.3.Market size and forecast, by sector
6.4.Korea (South Korea)
6.4.1.Key market trends and growth opportunities
6.4.2.Market size and forecast, by product
6.4.3.Market size and forecast, by sector
6.5.Kingdom of Saudi Arabia
6.5.1.Key market trends and growth opportunities
6.5.2.Market size and forecast, by product
6.5.3.Market size and forecast, by sector
6.6.Taiwan
6.6.1.Key market trends and growth opportunities
6.6.2.Market size and forecast, by product
6.6.3.Market size and forecast, by sector
6.7.Indonesia
6.7.1.Key market trends and growth opportunities
6.7.2.Market size and forecast, by product
6.7.3.Market size and forecast, by sector
6.8.Thailand
6.8.1.Key market trends and growth opportunities
6.8.2.Market size and forecast, by product
6.8.3.Market size and forecast, by sector
6.9.Malaysia
6.9.1.Key market trends and growth opportunities
6.9.2.Market size and forecast, by product
6.9.3.Market size and forecast, by sector
6.10.Canada
6.10.1.Key market trends and growth opportunities
6.10.2.Market size and forecast, by product
6.10.3.Market size and forecast, by sector
6.11.Vietnam
6.11.1.Key market trends and growth opportunities
6.11.2.Market size and forecast, by product
6.11.3.Market size and forecast, by sector
6.12.Rest of the World
6.12.1.Key market trends and growth opportunities
6.12.2.Market size and forecast, by product
6.12.3.Market size and forecast, by sector
CHAPTER 7:COMPANY PROFILES
7.1.BAXTER INTERNATIONAL INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.BIO PRODUCTS LABORATORY
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Key strategic moves and developments
7.3.BIOTEST AG
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.CSL LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRIFOLS SA
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.KEDRION S.P.A. (KEDRION BIOPHARMA INC.)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.LFB S. A
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.8.OCTAPHARMA AG
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.SANQUIN BLOOD SUPPLY FOUNDATION
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY PRODUCT, 2019–2027 (METRIC TONS)
TABLE 03.PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 04.PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 05.PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 06.PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 07.PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 08.PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 09.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 10.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 11.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 12.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 13.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 14.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 15.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 16.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 17.PUBLIC SECTOR PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 18.PUBLIC SECTOR PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 19.PUBLIC SECTOR PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.PUBLIC SECTOR PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 21.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 22.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 23.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 24.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 25.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 26.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 27.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & CAOAGULATION FACTOR IX, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & CAOAGULATION FACTOR IX, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 29.TURKEY PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 30.TURKEY PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 31.TURKEY PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 32.TURKEY PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 33.TURKEY PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 34.TURKEY PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 35.TURKEY PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 36.TURKEY PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 37.RUSSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 38.RUSSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 39.RUSSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 40.RUSSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 41.RUSSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 42.RUSSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 43.RUSSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 44.RUSSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 45.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 46.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN , 2019–2027 (METRIC TONS)
TABLE 47.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 48.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027, (MILLION INTERNATIONAL UNITS)
TABLE 49.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 50.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 51.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 52.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 53.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 54.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 55.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX , 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 56.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 57.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 58.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 59.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 60.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 61.TAIWAN PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 62.TAIWAN PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 63.TAIWAN PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 64.TAIWAN PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 65.TAIWAN PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 66.TAIWAN PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 67.TAIWAN PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 68.TAIWAN PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 69.INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 70.INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 71.INDONESIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 72.INDONESIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 73.INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 74.INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 75.INDONESIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 76.INDONESIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 77.THAILAND PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 78.THAILAND PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 79.THAILAND PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 80.THAILAND PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 81.THAILAND PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 82.THAILAND INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 83.THAILAND PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 84.THAILAND PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 85.MALAYSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 86.MALAYSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 87.MALAYSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX , 2019–2027 ($MILLION)
TABLE 88.MALAYSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 89.MALAYSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 90.MALAYSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 91.MALAYSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 92.MALAYSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 93.CANADA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 94.CANADA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 95.CANADA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX , 2019–2027 ($MILLION)
TABLE 96.CANADA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 97.CANADA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 98.CANADA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 99.CANADA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 100.CANADA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 101.VIETNAM PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 102.VIETNAM PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY PRODUCT, 2019–2027 (METRIC TONS)
TABLE 103.VIETNAM PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 104.VIETNAM PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 105.VIETNAM PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 106.VIETNAM PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 107.VIETNAM PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 108.VIETNAM PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 109.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 110.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 111.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 112.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 113.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 114.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 115.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 116.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 117.BAXTER: COMPANY SNAPSHOT
TABLE 118.BAXTER: PRODUCT SEGMENT
TABLE 119.BAXTER: PRODUCT PORTFOLIO
TABLE 120.BIO PRODUCTS LABORATORY: COMPANY SNAPSHOT
TABLE 121.BIO PRODUCTS LABORATORY: OPERATING SEGMENTS
TABLE 122.BIO PRODUCTS LABORATORY: PRODUCT PORTFOLIO
TABLE 123.BIOTEST AG: COMPANY SNAPSHOT
TABLE 124.BIOTEST AG: OPERATING SEGMENTS
TABLE 125.BIOTEST AG: PRODUCT PORTFOLIO
TABLE 126.CSL LTD: COMPANY SNAPSHOT
TABLE 127.CSL LTD..: OPERATING SEGMENT
TABLE 128.CSL LTD..: PRODUCT PORTFOLIO
TABLE 129.GRIFOLS: COMPANY SNAPSHOT
TABLE 130.GRIFOLS: OPERATING SEGMENTS
TABLE 131.GRIFOLS SA: PRODUCT PORTFOLIO
TABLE 132.KEDRION: COMPANY SNAPSHOT
TABLE 133.KEDRION: OPERATING SEGMENTS
TABLE 134.KEDRION: PRODUCT PORTFOLIO
TABLE 135.LFB: COMPANY SNAPSHOT
TABLE 136.LFB: OPERATING SEGMENTS
TABLE 137.LFB: PRODUCT PORTFOLIO
TABLE 138.OCTAPHARMA: COMPANY SNAPSHOT
TABLE 139.OCTAPHARMA: OPERATING SEGMENTS
TABLE 140.OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 141.SANQUIN BLOOD SUPPLY FOUNDATION: COMPANY SNAPSHOT
TABLE 142.SANQUIN BLOOD SUPPLY FOUNDATION: OPERATING SEGMENTS
TABLE 143.SANQUIN BLOOD SUPPLY FOUNDATION: PRODUCT PORTFOLIO
TABLE 144.TAKEDA: COMPANY SNAPSHOT
TABLE 145.TAKEDA: PRODUCT PORTFOLIO
TABLE 01.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY PRODUCT, 2019–2027 (METRIC TONS)
TABLE 03.PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 04.PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 05.PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 06.PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 07.PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 08.PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 09.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 10.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 11.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 12.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 13.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 14.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 15.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 16.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 17.PUBLIC SECTOR PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 18.PUBLIC SECTOR PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 19.PUBLIC SECTOR PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.PUBLIC SECTOR PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 21.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 22.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 23.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 24.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 25.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 26.PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY COUNTRY, 2019–2027 (METRIC TONS)
TABLE 27.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & CAOAGULATION FACTOR IX, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & CAOAGULATION FACTOR IX, BY COUNTRY, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 29.TURKEY PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 30.TURKEY PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 31.TURKEY PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 32.TURKEY PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 33.TURKEY PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 34.TURKEY PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 35.TURKEY PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 36.TURKEY PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 37.RUSSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 38.RUSSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 39.RUSSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 40.RUSSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 41.RUSSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 42.RUSSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 43.RUSSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 44.RUSSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 45.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 46.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN , 2019–2027 (METRIC TONS)
TABLE 47.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 48.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027, (MILLION INTERNATIONAL UNITS)
TABLE 49.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 50.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 51.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 52.SOUTH KOREA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 53.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 54.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 55.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX , 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 56.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 57.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 58.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 59.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 60.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 61.TAIWAN PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 62.TAIWAN PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 63.TAIWAN PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 64.TAIWAN PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 65.TAIWAN PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 66.TAIWAN PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 67.TAIWAN PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 68.TAIWAN PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 69.INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 70.INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 71.INDONESIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 72.INDONESIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 73.INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 74.INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 75.INDONESIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 76.INDONESIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 77.THAILAND PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 78.THAILAND PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 79.THAILAND PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 80.THAILAND PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 81.THAILAND PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 82.THAILAND INDONESIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 83.THAILAND PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 84.THAILAND PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 85.MALAYSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 86.MALAYSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 87.MALAYSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX , 2019–2027 ($MILLION)
TABLE 88.MALAYSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 89.MALAYSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 90.MALAYSIA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 91.MALAYSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 92.MALAYSIA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 93.CANADA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 94.CANADA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 95.CANADA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX , 2019–2027 ($MILLION)
TABLE 96.CANADA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 97.CANADA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 98.CANADA PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 99.CANADA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 100.CANADA PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 101.VIETNAM PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 102.VIETNAM PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY PRODUCT, 2019–2027 (METRIC TONS)
TABLE 103.VIETNAM PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 104.VIETNAM PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 105.VIETNAM PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 106.VIETNAM PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 107.VIETNAM PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 108.VIETNAM PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 109.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 ($MILLION)
TABLE 110.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, 2019–2027 (METRIC TONS)
TABLE 111.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 ($MILLION)
TABLE 112.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 113.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 ($MILLION)
TABLE 114.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR ALBUMIN & IMMUNOGLOBULIN, BY SECTOR, 2019–2027 (METRIC TONS)
TABLE 115.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 ($MILLION)
TABLE 116.REST OF THE WORLD PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY SECTOR, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 117.BAXTER: COMPANY SNAPSHOT
TABLE 118.BAXTER: PRODUCT SEGMENT
TABLE 119.BAXTER: PRODUCT PORTFOLIO
TABLE 120.BIO PRODUCTS LABORATORY: COMPANY SNAPSHOT
TABLE 121.BIO PRODUCTS LABORATORY: OPERATING SEGMENTS
TABLE 122.BIO PRODUCTS LABORATORY: PRODUCT PORTFOLIO
TABLE 123.BIOTEST AG: COMPANY SNAPSHOT
TABLE 124.BIOTEST AG: OPERATING SEGMENTS
TABLE 125.BIOTEST AG: PRODUCT PORTFOLIO
TABLE 126.CSL LTD: COMPANY SNAPSHOT
TABLE 127.CSL LTD..: OPERATING SEGMENT
TABLE 128.CSL LTD..: PRODUCT PORTFOLIO
TABLE 129.GRIFOLS: COMPANY SNAPSHOT
TABLE 130.GRIFOLS: OPERATING SEGMENTS
TABLE 131.GRIFOLS SA: PRODUCT PORTFOLIO
TABLE 132.KEDRION: COMPANY SNAPSHOT
TABLE 133.KEDRION: OPERATING SEGMENTS
TABLE 134.KEDRION: PRODUCT PORTFOLIO
TABLE 135.LFB: COMPANY SNAPSHOT
TABLE 136.LFB: OPERATING SEGMENTS
TABLE 137.LFB: PRODUCT PORTFOLIO
TABLE 138.OCTAPHARMA: COMPANY SNAPSHOT
TABLE 139.OCTAPHARMA: OPERATING SEGMENTS
TABLE 140.OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 141.SANQUIN BLOOD SUPPLY FOUNDATION: COMPANY SNAPSHOT
TABLE 142.SANQUIN BLOOD SUPPLY FOUNDATION: OPERATING SEGMENTS
TABLE 143.SANQUIN BLOOD SUPPLY FOUNDATION: PRODUCT PORTFOLIO
TABLE 144.TAKEDA: COMPANY SNAPSHOT
TABLE 145.TAKEDA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL NEUROVASCULAR DEVICES MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES (2018–2020)
FIGURE 03.TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2017–2020)
FIGURE 04.DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 05.TOP INVESTMENT POCKETS
FIGURE 06.MARKET SHARE ANALYSIS, 2019
FIGURE 07.HIGH BARGAINING POWER OF SUPPLIER
FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
FIGURE 09.HIGH THREAT OF SUBSTITUTES
FIGURE 10.MODERATE INTENSITY OF RIVALRYS
FIGURE 11.LOW THREAT OF NEW ENTRANTS
FIGURE 12.GERIATRIC POPULATION (%), 2017–2018
FIGURE 13.IMPACT ANALYSES, NEUROVASCULAR DEVICES MARKET
FIGURE 14.CLIPPINGS MARKET, 2019–2027 ($MILLION)
FIGURE 15.BARE DETATCHABLE COIL MARKET, 2019–2027 ($MILLION)
FIGURE 16.COATED DETATCHABLE MARKET, 2019–2027 ($MILLION)
FIGURE 17.COIL ASSIST STENTS MARKET, 2019–2027 ($MILLION)
FIGURE 18.COIL ASSIST BALLOON MARKET, 2019–2027 ($MILLION)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR EMBOLIZATION DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.CAROTID ARTERY STENT MARKET, 2019–2027 ($MILLION)
FIGURE 21.FLOW DIVERSION STENT MARKET, 2019–2027 ($MILLION)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR REVASCULARIZATION DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.CLOT RETRIEVAL DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 24.SUCTION AND ASPIRATION DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 25.SNARES MARKET, 2019–2027 ($MILLION)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR THROMBECTOMY DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.DISTAL FILTER DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 28.BALLOON OCCLUSION DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 30.MICROCATHETERS DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 31.MICROGUIDEWIRES DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 32.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR ACCESSORY DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 33.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR ANEURYSM, BY COUNTRY, 2019 & 2027 (%)
FIGURE 34.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2019 & 2027 (%)
FIGURE 35.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY COUNTRY, 2019 & 2027 (%)
FIGURE 36.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR STENOSIS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 37.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 38.U.S. NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 39.CANADA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 40.MEXICO NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 41.GERMANY NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 42.FRANCE NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 43.UK NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 44.ITALY NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 45.SPAIN NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 46.REST OF EUROPE NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 47.JAPAN NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 48.CHINA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 49.AUSTRALIA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 50.INDIA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 51.SOUTH KOREA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 52.REST OF ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 53.BRAZIL NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 54.SAUDI ARABIA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 55.SOUTH AFRICA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 56.REST OF LAMEA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 57.B.BRAUN: NET SALES, 2017–2019 ($MILLION)
FIGURE 58.B.BRAUN: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 59.B.BRAUN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 60.INTEGER: NET SALES, 2017–2019 ($MILLION)
FIGURE 61.INTEGER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 62.INTEGER: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 63.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 64.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 65.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 66.MICROPORT: NET SALES, 2017–2019 ($MILLION)
FIGURE 67.MICROPORT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 68.MICROPORT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 69.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 70.MEDTRONIC REVENUE SHARE, BY SEGMENTS, 2019 (%)
FIGURE 71.MEDTRONIC PLC: REVENUE SHARE, BY REGIONS, 2019 (%)
FIGURE 72.PENUMBRA: NET SALES, 2017–2019 ($MILLION)
FIGURE 73.PENUMBRA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 74.PENUMBRA: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 75.STRYKER: NET SALES, 2017–2019 ($MILLION)
FIGURE 76.STRYKER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 77.STRYKER: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 78.TERUMO: NET SALES, 2017–2019 ($MILLION)
FIGURE 79.TERUMO: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 80.TERUMO: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 01.GLOBAL NEUROVASCULAR DEVICES MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES (2018–2020)
FIGURE 03.TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2017–2020)
FIGURE 04.DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 05.TOP INVESTMENT POCKETS
FIGURE 06.MARKET SHARE ANALYSIS, 2019
FIGURE 07.HIGH BARGAINING POWER OF SUPPLIER
FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
FIGURE 09.HIGH THREAT OF SUBSTITUTES
FIGURE 10.MODERATE INTENSITY OF RIVALRYS
FIGURE 11.LOW THREAT OF NEW ENTRANTS
FIGURE 12.GERIATRIC POPULATION (%), 2017–2018
FIGURE 13.IMPACT ANALYSES, NEUROVASCULAR DEVICES MARKET
FIGURE 14.CLIPPINGS MARKET, 2019–2027 ($MILLION)
FIGURE 15.BARE DETATCHABLE COIL MARKET, 2019–2027 ($MILLION)
FIGURE 16.COATED DETATCHABLE MARKET, 2019–2027 ($MILLION)
FIGURE 17.COIL ASSIST STENTS MARKET, 2019–2027 ($MILLION)
FIGURE 18.COIL ASSIST BALLOON MARKET, 2019–2027 ($MILLION)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR EMBOLIZATION DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.CAROTID ARTERY STENT MARKET, 2019–2027 ($MILLION)
FIGURE 21.FLOW DIVERSION STENT MARKET, 2019–2027 ($MILLION)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR REVASCULARIZATION DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.CLOT RETRIEVAL DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 24.SUCTION AND ASPIRATION DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 25.SNARES MARKET, 2019–2027 ($MILLION)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR THROMBECTOMY DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.DISTAL FILTER DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 28.BALLOON OCCLUSION DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 30.MICROCATHETERS DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 31.MICROGUIDEWIRES DEVICES MARKET, 2019–2027 ($MILLION)
FIGURE 32.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR ACCESSORY DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 33.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR ANEURYSM, BY COUNTRY, 2019 & 2027 (%)
FIGURE 34.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2019 & 2027 (%)
FIGURE 35.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY COUNTRY, 2019 & 2027 (%)
FIGURE 36.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR STENOSIS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 37.COMPARATIVE SHARE ANALYSIS OF NEUROVASCULAR DEVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 38.U.S. NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 39.CANADA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 40.MEXICO NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 41.GERMANY NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 42.FRANCE NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 43.UK NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 44.ITALY NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 45.SPAIN NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 46.REST OF EUROPE NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 47.JAPAN NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 48.CHINA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 49.AUSTRALIA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 50.INDIA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 51.SOUTH KOREA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 52.REST OF ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 53.BRAZIL NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 54.SAUDI ARABIA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 55.SOUTH AFRICA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 56.REST OF LAMEA NEUROVASCULAR DEVICES MARKET, 2020–2027 ($MILLION)
FIGURE 57.B.BRAUN: NET SALES, 2017–2019 ($MILLION)
FIGURE 58.B.BRAUN: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 59.B.BRAUN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 60.INTEGER: NET SALES, 2017–2019 ($MILLION)
FIGURE 61.INTEGER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 62.INTEGER: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 63.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 64.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 65.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 66.MICROPORT: NET SALES, 2017–2019 ($MILLION)
FIGURE 67.MICROPORT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 68.MICROPORT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 69.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 70.MEDTRONIC REVENUE SHARE, BY SEGMENTS, 2019 (%)
FIGURE 71.MEDTRONIC PLC: REVENUE SHARE, BY REGIONS, 2019 (%)
FIGURE 72.PENUMBRA: NET SALES, 2017–2019 ($MILLION)
FIGURE 73.PENUMBRA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 74.PENUMBRA: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 75.STRYKER: NET SALES, 2017–2019 ($MILLION)
FIGURE 76.STRYKER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 77.STRYKER: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 78.TERUMO: NET SALES, 2017–2019 ($MILLION)
FIGURE 79.TERUMO: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 80.TERUMO: REVENUE SHARE, BY REGION, 2019 (%)
